Molecular Biology Reports

, Volume 38, Issue 6, pp 4219–4224 | Cite as

Comparison of gene expression profiles reveals aberrant expression of FOXO1, Aurora A/B and EZH2 in lesional psoriatic skins

  • Yayan Liu
  • Wenhui Luo
  • Shuai Chen


Psoriasis is a chronic, non-infectious skin disease affects 2–3% of the population worldwide. In order to find genes possibly cause this skin disease, we re-analyzed the gene expression data-sets from three published studies. We compared the gene expression profiles between lesional psoriatic skin (PP), uninvolved psoriatic skin (PN) and normal skin (NN) tissues. We found that compared with in PN and NN tissues, the expression of FOXO1 is significantly repressed and the expression of AURKA, AURKB and EZH2 is significantly up-regulated in PP tissues (P < 0.001). During the treatment of psoriasis patients with TNF-α antagonist Etanercept, the expression of FOXO1 was re-activated and the expression of AURKA and EZH2 was repressed. These results suggest loss of FOXO1 expression and elevated AURKA/B and EZH2 expression in lesional psoriatic tissues have potential contribution to the development of psoriasis. It is worthwhile to test whether the combination of Aurora kinases or EZH2 inhibitors can enhance the therapeutic effects of Etanercept in psoriasis management.


Psoriasis Microarray FOXO1 Aurora kinases EZH2 Etanercept 

Supplementary material

11033_2010_544_MOESM1_ESM.xls (243 kb)
Supplementary material 1 (XLS 243 kb)
11033_2010_544_MOESM2_ESM.xls (182 kb)
Supplementary material 2 (XLS 181 kb)


  1. 1.
    Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. N Engl J Med 361:496–509PubMedCrossRefGoogle Scholar
  2. 2.
    Bowcock AM, Krueger JG (2005) Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol 5:699–711PubMedCrossRefGoogle Scholar
  3. 3.
    Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D et al (2009) Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappa B pathways. Nat Genet 41:199–204PubMedCrossRefGoogle Scholar
  4. 4.
    Bhalerao J, Bowcock AM (1998) The genetics of psoriasis: a complex disorder of the skin and immune system. Hum Mol Genet 7:1537–1545PubMedCrossRefGoogle Scholar
  5. 5.
    Kunz M (2008) DNA microarray technology in dermatology. Semin Cutan Med Surg 27:16–24PubMedCrossRefGoogle Scholar
  6. 6.
    Gudjonsson JE, Ding J, Li X, Nair RP, Tejasvi T, Qin ZS et al (2009) Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. J Invest Dermatol 129:2795–2804PubMedCrossRefGoogle Scholar
  7. 7.
    Yao Y, Richman L, Morehouse C, de Los Reyes M, Higgs BW, Boutrin A, White B, Coyle A, Krueger J, Kiener PA, Jallal B (2008) Type I interferon: potential therapeutic target for psoriasis? PLoS One 3:e2737PubMedCrossRefGoogle Scholar
  8. 8.
    Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J, Nograles KE, Guttman-Yassky E, Cardinale I, Lowes MA, Krueger JG (2009) Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 124:1022–1030PubMedCrossRefGoogle Scholar
  9. 9.
    Li C, Wong WH (2001) Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 98:31–36PubMedCrossRefGoogle Scholar
  10. 10.
    Sturn A, Quackenbush J, Trajanoski Z (2002) Genesis: cluster analysis of microarray data. Bioinformatics (Oxford, England) 18:207–208CrossRefGoogle Scholar
  11. 11.
    Eckert RL, Broome AM, Ruse M, Robinson N, Ryan D, Lee K (2004) S100 proteins in the epidermis. J Invest Dermatol 123:23–33PubMedCrossRefGoogle Scholar
  12. 12.
    Potente M, Urbich C, Sasaki K, Hofmann WK, Heeschen C, Aicher A, Kollipara R, DePinho RA, Zeiher AM, Dimmeler S (2005) Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. J Clin Invest 115:2382–2392PubMedCrossRefGoogle Scholar
  13. 13.
    Furuyama T, Kitayama K, Shimoda Y, Ogawa M, Sone K, Yoshida-Araki K, Hisatsune H, Nishikawa S, Nakayama K, Nakayama K, Ikeda K, Motoyama N, Mori N (2004) Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice. J Biol Chem 279:34741–34749PubMedCrossRefGoogle Scholar
  14. 14.
    Chua RA, Arbiser JL (2009) The role of angiogenesis in the pathogenesis of psoriasis. Autoimmunity 42:574–579PubMedCrossRefGoogle Scholar
  15. 15.
    Carmena M, Earnshaw WC (2003) The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 4:842–854PubMedCrossRefGoogle Scholar
  16. 16.
    Dutertre S, Descamps S, Prigent P (2002) On the role of aurora-A in centrosome function. Oncogene 21:6175–6183PubMedCrossRefGoogle Scholar
  17. 17.
    Adams RR, Carmena M, Earnshaw WC (2001) Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol 11:49–54PubMedCrossRefGoogle Scholar
  18. 18.
    Sparmann A, van Lohuizen M (2006) Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6:846–856PubMedCrossRefGoogle Scholar
  19. 19.
    Simon JA, Kingston RE (2009) Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 10:697–708PubMedGoogle Scholar
  20. 20.
    Campos EI, Reinberg D (2009) Histones: annotating chromatin. Annu Rev Genet 43:559–599PubMedCrossRefGoogle Scholar
  21. 21.
    Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM et al (2006) Control of developmental regulators by polycomb in human embryonic stem cells. Cell 125:301–313PubMedCrossRefGoogle Scholar
  22. 22.
    Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A et al (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40:499–507PubMedCrossRefGoogle Scholar
  23. 23.
    Ezhkova E, Pasolli HA, Parker JS, Stokes N, Su IH, Hannon G et al (2009) Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell 136:1122–1135PubMedCrossRefGoogle Scholar
  24. 24.
    Zenz R, Eferl R, Kenner L, Florin L, Hummerich L et al (2005) Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 437:369–375PubMedCrossRefGoogle Scholar
  25. 25.
    Galindo MP, Bartlett BL, Gewirtzman A, Mendoza N, Tremaine AM, Tyring SK (2008) Etanercept: an overview of its role in the treatment of psoriasis. Expert Opin Drug Metab Toxicol 4:305–310PubMedCrossRefGoogle Scholar
  26. 26.
    Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58:826–850PubMedCrossRefGoogle Scholar
  27. 27.
    Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 58:851–864PubMedCrossRefGoogle Scholar
  28. 28.
    Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JM, Miller KM (2004) VX-680, a potent and selective small-molecule inhibitor of the aurora kinases, suppresses tumor growth in vivo. Nat Med 10:262–267PubMedCrossRefGoogle Scholar
  29. 29.
    Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q (2007) Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21:1050–1063PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  1. 1.Masonic Cancer CenterUniversity of MinnesotaMinneapolisUSA
  2. 2.Department of DermatologyZhuzhou No. 1 HospitalZhuzhou CityP. R. China

Personalised recommendations